-

Shareholder Alert: Robbins LLP Announces It Is Investigating Immunomedics, Inc. (IMMU) for Misleading Shareholders

SAN DIEGO & MORRIS PLAINS, N.J.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that it is investigating Immunomedics, Inc. (NASDAQ: IMMU) for alleged violations of the Securities Exchange Act of 1934 and whether the Company's officers and directors breached their fiduciary duties to shareholders. Immunomedics, a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer. The company is developing its antibody-drug conjugate IMMU-12.

If you suffered a loss as a result of Immunomedics' misconduct, click here.

Immunomedics, Inc. (IMMU) Drug Presentation Removed From ASCO Meeting

On April 19, 2016, Immunomedics announced that the Company would present updated results for IMMU-132 treatment at The American Society of Clinical Oncology ("ASCO"). However, on June 2, 2016, media outlets reported that ASCO had removed Immunomedics regarding the Company's IMMU-132 breast cancer drug from ASCO's annual meeting. ASCO explained their decision, revealing that Immunomedics misrepresented that the Company's abstract for IMMU-132 contained updated and previously undisclosed results from a mid-stage study, when in fact that data was actually old and previously seen. On this news, Immunomedics' stock fell almost 15% to close at $4.52 per share on June 3, 2016. Finally, on June 1, 2020, U.S. District Judge Katharine S. Hayden denied Immunomedics' motion to dismiss, stating that the plaintiff had sufficiently alleged the Company had made false or misleading statements about its ASCO presentation. Her decision paves the way for litigation to proceed.

Immunomedics, Inc. (IMMU) Shareholders Have Legal Options

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Want to be notified if a class action against Immunomedics settles? Want to receive free alerts about companies engaged in wrongdoing? Sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
LKandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

Industry:

Robbins LLP

NASDAQ:IMMU
Release Versions
English
$Cashtags
$IMMU
Hashtags
#ClassAction
#Finance
#Investment
#Investor
#Lawsuit
#Securities
#Shareholder
#Shareholderrights
#StockAlert
#StockMarketData
#StockNews
#StockTrading
#Stocks
#Trader
#shareholderrightslawfirm

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
LKandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Stockholder Notice: Robbins LLP Informs Investors of the Hercules Capital, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Hercules Capital, Inc. (NYSE: HTGC) securities between May 1, 2025 and February 27, 2026. Hercules Capital is a private credit firm, also known a Business Development Company, which specializes in making private loans to companies. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Al...

Investor Notice: Robbins LLP Informs Investors of the Power Solutions International, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Power Solutions International, Inc. (NASDAQ: PSIX) securities between May 8, 2025 and March 2, 2026. Power Solutions designs, manufactures, and sells engines and power systems. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations tha...

Robbins LLP Urges KD Stockholders to Contact the Firm for Information About the Class Action Against Kyndryl Holdings, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Kyndryl Holdings, Inc. (NYSE: KD) securities between August 7, 2024 and February 9, 2026. Kyndryl describes itself as a “technology services company, which engages in the provision of infrastructure services.” For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What is the class period? Au...
Back to Newsroom